Remicade / Infliximab Long Term safety profile research - Imperial College London

Very interesting research by Imperial College London on Remicade / Infliximab. Had been doing some reasearch as im tossing up between this and entyvio. Apologies if it has been posted before.

https://www.researchgate.net/publication/318146352_The_risk_of_cancer_in_Inflammatory_Bowel_Disease_Does_infliximab_contribute_to_cancer_risk


Definately has given me food for thought, not to fear biliogics as much as I had been. Actually now maybe preferring Remicade to Entyvio, considering the supposed quicker results, and lenth of time its been in use.

As I say apologies if it has been posted before. Thought it may benefit someone else who is in a quandrum. Quite difficult to find long term studies with clear comparative analysis on anything.

Regards,

Stephen

/www.researchgate.net/publication/318146352_The_risk_of_cancer_in_Inflammatory_Bowel_Disease_Does_infliximab_contribute_to_cancer_risk


interesting. I think the gist of the CRC risk had been mentioned here a lot. It is nice to see it quantified as about 2-fold increase. But the finding of no increased risk for non-Remicade (presumably non-biologic) folks is new.

I think the general wisdom I read on this forum has been the risk of not Remicade for CRC is likely greater than the risk of lymphoma from Remicade. (or at least no higher than 6mp/thiopurines)

Given that the phase-I and phase-III trials for Remicade had found some increased risk for lymphoma, it is interesting that this was not found in this study using a larger population sample.

It is not clear (from the abstract) if the non-Remicade group was untreated or well-managed with other meds. Some like 6mp carry their own risk of lymphoma. The exact composition of the groups being compared is always very important in approaching these kinds of results.